Thank you.
Thanks to all of the witnesses for their really stimulating testimony.
I have a short amount of time left for questions. I think I'd like to start with you, Doctors Lam and Ionescu, if I could, because I was really taken by your testimony about the effect of low-dose CT scanning in high-risk populations.
Dr. Lam, I was particularly struck by what you referred to as I think the four “innovations”. I was having a little trouble understanding it as I put that together with your first idea of an electronic lung cancer predictive tool. You said it was very advanced, and then you talked about the genomic signature.
Dr. Ionescu, you talked about the two biomarkers that are particularly appropriate for lung cancer.
Were you talking about similar things? Or was the biomarker analysis different from the electric predictive tool or the genomic signature that you, Dr. Lam, were talking about? Maybe you could explain that to me.